Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05101018
PHASE4

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

Sponsor: James J. Peters Veterans Affairs Medical Center

View on ClinicalTrials.gov

Summary

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2021-11-01

Completion Date

2027-11-01

Last Updated

2025-09-17

Healthy Volunteers

No

Interventions

DRUG

Romosozumab

Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month

DRUG

Denosumab

Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months

Locations (2)

Kessler Institute for Rehabilitation

West Orange, New Jersey, United States

James J. Peters VA Medical Center

The Bronx, New York, United States